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Rapid, real time pathology review for
ECOG/ACRIN 1412: a novel and successful
paradigm for future lymphoma clinical
trials in the precision medicine era
Rebecca L. King 1, Grzegorz S. Nowakowski1, Thomas E. Witzig1, David W. Scott2, Richard F. Little3, Fangxin Hong4,
Randy D. Gascoyne2, Brad S. Kahl5 and William R Macon1
Abstract
ECOG/ACRIN 1412 (E1412) is a randomized, phase II open-label study of lenalidomide/RCHOP vs. RCHOP alone in
adults with newly diagnosed de novo diffuse large B-cell lymphoma (DLBCL) and requires NanoString gene expression
proﬁling (GEP) for cell-of-origin testing. Because of high ineligibility rate on retrospective expert central pathology
review (ECPR), real-time (RT) ECPR was instituted to conﬁrm diagnosis and ensure adequate tissue for GEP prior to
study enrollment. Goal was notiﬁcation of eligibility within 2 working days (WD). Initially, 208 patients were enrolled, 74
(35.6%) of whom were deemed ineligible by retrospective ECPR. After initiation of RT-ECPR, 219 patients were
registered. Of these, 73 (33.3%) were ineligible and were declined enrollment; 47 (21.5% of total) had an ineligible
diagnosis on RT-ECPR, and 26 (11.9% of total) had inadequate tissue. Because the 73 ineligible patients were never
enrolled, no study slots were “lost” during this phase. Notiﬁcation of eligibility occurred in an average of 1 WD (Range
0–4) with 97.3% within 2 WD. This novel RT-ECPR serves as a model for future lymphoma trials. Real-time ECPR can
help to reduce costs and ensure that study slots accurately reﬂect the targeted population. In the precision-medicine
era, rapid collection of relevant pathology/biomarker data is essential to trial success.
Introduction
Lymphoma diagnostics has become an increasingly
complex and evolving ﬁeld, requiring integration of
multiple testing modalities and an in-depth under-
standing of current World Health Organization (WHO)
classiﬁcation schemes, as well as National Clinical
Cancer Network (NCCN) therapeutic guidelines1–3. In
2016, an updated revision of the WHO classiﬁcation of
lymphoid neoplasms was published (WHO 2016),
underscoring this fact and placing emphasis on multi-
modality diagnostics integrating histopathologic review,
immunohistochemistry (IHC), ﬂow cytometry, cytoge-
netic, and molecular genetic testing1,2.
In no single disease category is this paradigm shift more
evident than in diffuse large B-cell lymphoma (DLBCL).
The revised WHO 2017 requires the identiﬁcation of
germinal center B-like (GCB) and activated B-cell-like
(ABC) subtypes of DLBCL. Although gene expression
proﬁling (GEP) is required to accurately identify these,
IHC algorithms will be considered acceptable since GEP is
not widely available as a routine clinical test. Additionally,
accurate diagnosis requires methods such as ﬂuorescence
in situ hybridization (FISH) to evaluate for rearrange-
ments involving MYC, BCL2, and BCL61,2. Not only do
these studies allow us to better subclassify DLBCL based
on its underlying biologic features, but more importantly
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they predict prognosis, and are increasingly important for
therapy selection in the era of precision medicine4–15.
Although DLBCL is the most common lymphoma in
the United States and other Western countries, it is still
relatively rare (6.9 cases/100,000 people; ~1% of all new
cancer cases) compared with non-lymphoid malignancies,
and thus may pose a challenge to pathologists who do not
frequently encounter these types of diseases in their
practice16–18. In addition, pathologists at smaller centers
may not have ready access to the increasingly complex
array of diagnostic tools necessary to accurately evaluate
lymphoma cases. Previous studies evaluating lymphoma
cases sent for expert central pathology review (ECPR)
support this assertion, indicating variable rates of dis-
crepancy ranging from 5 to 25%8,19–27. In fact, one ret-
rospective study evaluating rates of discrepancy on ECPR
amongst all types of surgical pathology cases, suggest that
lymphoma/lymph node specimens have the second
highest rate of discordance at 16%26.
ECOG/ACRIN 1412 (E1412) is a randomized phase II
open-label study of lenalidomide/RCHOP (R2CHOP) vs.
RCHOP alone in patients ≥ 18 years of age with newly
diagnosed de novo DLBCL. The trial statistical design is
powered to determine the effects of the two treatment
arms independently in GCB and ABC subtypes of DLBCL
as determined by NanoString (GEP) on parafﬁn-
embedded tumor tissue6. This mandated that ECPR be
conducted not only to conﬁrm the diagnosis of DLBCL
and but also to ensure that adequate tissue was available
for NanoString COO testing. At trial initiation, the ECPR
was performed in a standard fashion, after subject ran-
domization and after treatment had been initiated.
At approximately 50% subject accrual, data analysis
indicated a high rate of patient ineligibility in addition to
delays in receipt of pathology materials at the ECPR site
for up to 1–2 years post-enrollment. As such, the protocol
was amended to include a requirement for rapid, real-
time (RT) ECPR to determine patient eligibility prior to
study enrollment and randomization to therapy. ECPR
included both tissue adequacy assessment for required
COO testing, as well as conﬁrmation of the submitted
diagnosis. Here we present data on the 427 patients
submitted for ECPR in E1412 emphasizing the impor-
tance, effectiveness, and feasibility of rapid, RT-ECPR for
a DLBCL clinical trial.
Methods
Pathology eligibility criteria for ECOG/ACRIN 1412
For inclusion in E1412 patients were required to have a
diagnosis of de novo DLBCL, based on the WHO 2008
criteria, without evidence of a concurrent low grade B-cell
lymphoma. NanoString (NanoString Technologies, Seat-
tle, WA) GEP testing by the Lymph2Cx method was
required for COO subtyping and ultimate assessment of
treatment outcomes by subtype6. Therefore, a tissue block
or unstained slide sections (USS) were required as follows:
2 sections if ≥1 cm2 tumor; 5 sections if 0.1–1 cm2 tumor;
10 sections if <0.1 cm2 tumor6. Exclusionary diagnoses
included: T cell/histiocyte-rich large B-cell lymphoma,
primary mediastinal (thymic) large B-cell lymphoma,
central nervous system DLBCL, B-cell lymphoma,
unclassiﬁable, with features intermediate between DLBCL
and Burkitt lymphoma (WHO 2008)1, B-cell lymphoma,
unclassiﬁable, with features intermediate between DLBCL
and classical Hodgkin lymphoma (WHO 2008)1, DLBCL
with a concurrent low grade B-cell lymphoma or nodular
lymphocyte predominant Hodgkin lymphoma, all non-
DLBCL subtypes of B-cell lymphoma including follicular
lymphoma, marginal zone lymphoma, mantle cell lym-
phoma, and B-cell lymphoma, not further classiﬁable.
Pre-amendment ECPR
Patients were enrolled and assessed for eligibility based
on reported diagnosis of DLBCL from the enrolling center
and other clinical and laboratory features as per the study
protocol. ECPR was performed retrospectively in the
Division of Hematopathology, Mayo Clinic, Rochester,
MN by at least one of two designated hematopathologists
(RLK and WRM) as materials were received by the review
site. Retrospective ECPR occurred from the date of study
opening 14 May 2013 until 30 November 2015. This
process is summarized in Fig. 1 (left panel).
Post-amendment ECPR
Following protocol amendment (effective 1 December
2015 to date of study closure 17 January 2017), RT-ECPR
by at least one of the two study pathologists was required
prior to study enrollment. This was termed “Step 0” in
the enrollment process. Details of this process are illu-
strated in Fig. 1 (right panel). Prior to completing
enrollment of an otherwise eligible patient, enrolling sites
submitted pathology materials including Hematoxylin
and Eosin (H&E) stained slide of representative tumor
along with a CD20 IHC slide and either a tissue block
or 10 USS containing tumor. If a diagnosis of de novo
DLBCL was conﬁrmed and sufﬁcient tissue was available
for COO typing, the patient was considered eligible
and the enrolling site was notiﬁed immediately via
fax through a standardized “Step 0” enrollment form.
Patients would then proceed with enrollment and ran-
domization of therapy. If the diagnosis was not conﬁrmed,
or insufﬁcient tissue remained, the enrolling site was
likewise notiﬁed immediately and the patient did not
proceed to enrollment on study. Protocol goal was noti-
ﬁcation within 2 working days of receipt of material at the
ECPR site.
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Data collection and analysis
Date of receipt of pathology materials by a study assis-
tant in the Division of Hematopathology at the Mayo
Clinic was recorded in each case and abstracted for this
study. A Step 0 form was then attached and the materials
were provided to one of the two ECPR pathologists. If
only a tissue block was provided, an H&E, CD20 and USS
were expedited and were available to the pathologist
within 24 h. In these instances, date of receipt was indi-
cated as the ﬁrst date any material was received, not the
actual date of pathology review. Date of notiﬁcation of the
enrolling site was recorded on the “Step 0” enrollment
forms.
Turnaround time (TAT) for notiﬁcation of enrolling
sites was calculated using the time interval (in days)
between the date of receipt of materials (Day 0) and the
date of notiﬁcation, with exclusion of weekends. TAT for
time from date of original pathology report to date of
ECPR was calculated between the date the original
pathology report was signed out and the date material was
reviewed by a pathologist at the ECPR site, excluding
weekends.
For eligible patients, USS or tissue curls were mailed
from the ECPR site to a separate laboratory (British
Columbia Cancer Agency, Vancouver, BC) for Nano-
String COO testing. Completion of COO testing was not
required for assessment of study eligibility and was not
performed in real-time.
Submitting diagnosis, ECPR diagnosis, eligibility status,
and reason for ineligibility (if applicable) were recorded in
Fig. 1 Schematic of traditional vs. real-time expert central pathology review
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a database for each patient. Patients were classiﬁed as
either pre-amendment (retrospective review) or post-
amendment (RT review).
Results
In total, 208 patients were enrolled in E1412 prior to the
study amendment over 930 days. During this phase,
pathology materials were received at the ECPR site an
average of 277 days following the date the original
pathology report was issued (range 191–782 days). Of 208
enrolled, 74 patients (35.6%) were deemed ineligible by
ECPR, either because of an ineligible diagnosis on ECPR
(47, 63.5%) or inadequate tissue for the required testing/
conﬁrmation of diagnosis (27, 36.4%). When reﬂected as
percent of total enrolled (208), 22.6% of patients had an
ineligible diagnosis, and 13.0% had inadequate tissue
(Table 1). Due to the retrospective nature of the ECPR
during this phase, all 74 of these study slots were “lost” as
patients had already been randomized and treated on
study (Fig. 1). The remaining 134 patients were con-
sidered eligible for future analysis.
Following amendment of the study to include RT-
ECPR, 219 additional patients were submitted for Step 0
review during a 413 day period. During this phase,
because of the requirement for pre-enrollment pathology
review, pathology materials were received much more
quickly at the ECPR site, although not always expedi-
tiously (average 17 days, range 2–95 days). Of the 219
patients, 73 (33.3%) were ineligible and were declined
enrollment either because of an ineligible diagnosis on
ECPR (47, 64.4%), or inadequate tissue (26, 35.6%).When
reﬂected as percent of total submitted (219), 21.5% of
patients had an ineligible diagnosis, and 11.9% had
inadequate tissue (Table 1). Because the 73 ineligible
patients were never enrolled on study, no study slots were
“lost” during this phase (Fig. 1).
A total of 280 patients were eligible for analysis based
on ECPR for E1412. This number represents 65.6% of
those submitted, and thus a rejection/ineligibility rate of
34.4%. The total rejection rate due to ECPR determination
of an ineligible diagnosis was 22.0% (94 cases). The
majority of these were due to discordance between the
referring site and the ECPR diagnosis (72 cases), while a
signiﬁcant subset represented cases submitted by the
referring center with an ineligible diagnosis documented
on the original pathology report, with which the ECPR
agreed (22 cases). Of these 22, 7 were submitted prior to
the amendment, while 15 were submitted after the
amendment (Table 1).
The most common ECPR diagnosis among rejected
cases was DLBCL occurring with another concurrent
lymphoma, usually low grade, which was not appreciated
on the initial diagnostic evaluation (39 cases, 9.1% of total
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DLBCL and ECPR disagreed and diagnosed a non-DLBCL
subtype of lymphoma (follicular lymphoma, marginal
zone lymphoma, or B-cell lymphoma, unclassiﬁable) were
also frequent (39, 9.1%). A summary of cases with ineli-
gible diagnoses is shown in Table 2.
Of 147 rejected cases, 65 (42.2%) were core/needle
biopsies, 4 (2.6%) were cell blocks made from ﬁne needle
aspiration, and 78 (50.6%) were other types of excisional
biopsies, punch biopsies, or resections. These numbers
are similar to the overall study cohort (42.3% core/needle
biopsies, 1.3% cell blocks). Among rejected cases, those
with inadequate tissue had a higher proportion of core
biopsies and cell blocks than those rejected for an ineli-
gible diagnosis (71.6 vs. 24.1%, p < 0.05, Fisher’s exact).
Rates of rejection were similar between cases reviewed
initially at academic medical centers and from private
hospitals/ laboratories (32.1 vs. 30.4%, p= 0.74, Fisher’s
exact).
Post-amendment, the protocol goal was notiﬁcation of
enrolling sites within 2 working days and this was
achieved in 97.3% of cases. When this was not achieved, it
could usually be attributed to non-working holidays or
cases received with only a tissue block and no stained
slides for review. Average time to notiﬁcation was 1
working day (range 0–4).
Although not required to be completed for enrollment,
the amendment allowed for the additional GEP testing
necessary for the study to be performed efﬁciently. All of
this testing was completed on the 146 post-amendment
patients within 6 weeks of receipt of their materials.
Completion of this same testing for the pre-enrollment
cohort took 1–2 years in some cases, due to delays in
receipt of materials at the ECPR site.
Discussion
This report is the ﬁrst to detail experience and success
with rapid, RT-ECPR prior to study enrollment for a
multicenter National Clinical Trials Network lymphoma
clinical trial. Although DLBCL represents the most
common lymphoma in Western populations, the overall
rate of pathology ineligibility for E1412 was high at 34.4%.
This rate encompasses two major issues, neither of which
is unique to this study: changes of diagnosis based on
ECPR and having inadequate tissue to perform the diag-
nostic, prognostic and predictive studies necessary to test
the hypotheses of the clinical trial.
Our results support the recent, large-scale study from
France, in which expert, RT central pathology review of
lymphomas was performed on over 42,000 patients
between 2010 and 201327. The overall rate of diagnostic
change between referral and expert review in the French
study was 19.7%, similar to our rate of 16.9%27. As in the
US, DLBCL represents the most common lymphoma in
their population, and accordingly was the most common
lymphoma in their cohort at approximately one-third of
total cases reviewed. Other studies have noted similar
ﬁndings, with a discordance rate of up to 25.8% after
expert review for DLBCL cases (one of the highest rates
among the lymphoma types studied) in a London Regio-
nal Cancer network19. In fact, when comparing dis-
cordance rates amongst different specimen types in a US
referral practice, rates of lymph node/lymphoma dis-
cordance after expert review were 16%, second only to
gastrointestinal specimens, and higher than others
including gynecologic, breast, bone/soft tissue, pulmon-
ary, and others26. While some recent US-based clinical
trials have shown lower rates of rejection due to ineligible
diagnosis, their inclusion criteria and tissue requirements
differed from those of E1412 in various ways, and thus
cannot be directly compared28–33. The results of our
study, as well as these others, highlight that, despite its
prevalence, the diagnosis of DLBCL is challenging for
pathologists and prone to misdiagnosis.
In the clinical trial setting such as this one, enrollment
of patients with diagnoses that are ineligible can compli-
cate data analysis leading to loss of study power to
Table 2 Summary of cases submitted in which the diagnosis was found to be ineligible by ECPR
Exclusionary diagnoses Total cases Pre-amendment Post-amendment
T cell/histiocyte-rich large B-cell lymphoma 4 1 3
B-cell lymphoma, unclassiﬁable, with features intermediate between DLBCL and BLa 8 2 6
B-cell lymphoma, unclassiﬁable, with features intermediate between DLBCL and classical
Hodgkin lymphoma
1 1 0
DLBCL with a concurrent low-grade B-cell lymphoma or NLPHL 39 18 21
Non-DLBCL subtypes of B-cell lymphoma (FL, MZL, unclassiﬁable, etc.) 39 23 16
Cannot conﬁrm lymphoma on slides 3 2 1
Total 94 47 47
aWHO 2008 Classiﬁcation
FL follicular lymphoma, MZL marginal zone lymphoma, NLPHL nodular lymphocyte predominant Hodgkin lymphoma
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evaluate the planned endpoints. Speciﬁcally, as more
DLBCL clinical trials require COO analysis to assess
treatment efﬁcacy in different subgroups, the ability to
assess in real time not only the diagnosis, but certain
pathologic features, as well as the adequacy of tissue for
molecular genetic testing is critical. In addition, when a
clinical trial is written with a speciﬁc subgroup of patients
in mind (for example de novo DLBCL), and with certain
exclusionary diagnoses, it is critical that CPR be per-
formed to ensure that the enrolled population accurately
reﬂects the study as written. Although current standard
therapy may be similar for two diseases, that does not
necessarily indicate that they should be included as one
entity in a clinical trial setting. For example, although T
cell/histiocyte-rich large B cell lymphoma has a similar
standard therapy to DLBCL, NOS, these two represent
pathologically distinct disease processes and in a research
setting should be treated as distinct entities in order to
assess for potential therapeutic advances in each disease
individually.
The impact to patients of mis-classiﬁcation of
lymphoma which this study and others have highlighted is
important outside the clinical trial realm, as well. While
many of the diagnostic revisions identiﬁed in this study
would likely have minimal impact on routine patient
care (for example identiﬁcation of a concurrent low grade
lymphoma in the background of DLBCL), a signiﬁcant
percentage of our revisions (39/94, 41.5%) were cases
submitted as DLBCL that in fact had only low grade
lymphoma or lymphoma that was unclassiﬁable based on
the tissue submitted. Changes such as these would
have signiﬁcant impact on therapy selection, as these
patients would typically not require R-CHOP che-
motherapy routinely used for DLBCL, but would be
treated with less aggressive regimens. Furthermore,
patients revised to a diagnosis of B-cell lymphoma,
unclassiﬁable, with features intermediate between DLBCL
and BL (WHO 2008), would be expected to frequently
receive escalated therapy in accordance with a more
aggressive disease process.
While this study did not directly evaluate the clinical
impact of diagnostic revision, Laurent et al. reported a
17.4% overall rate of diagnostic change with potential
impact on patient care27. Similarly, Proctor et al. reported
that 11% of cases with discordant lymphoma diagnoses on
secondary review would have signiﬁcant change in clinical
management. Furthermore, they reported that 39% would
have a minor impact on patient care, and the remaining
50% would have resulted in delayed or inappropriate
therapy without the secondary review25. Finally similar
results were presented in a study by Bowen et al, evalu-
ating review of referred lymphoma diagnoses at a single
academic center. In their study, 12.9% of reviewed cases
had a major diagnostic change resulting in therapeutic
change following secondary review. Interestingly, their
study speciﬁcally evaluated diagnostic revision from aca-
demic vs. non-academic centers, and found higher rates of
discordance from non-academic centers. In contrast,
perhaps surprisingly, our study did not ﬁnd such a dif-
ference (academic 32.1% vs. non-academic 30.4%, p=
0.74, Fisher’s exact). It is uncertain what accounts for this
difference, although we speculate that the line between
academic and non-academic practice has become
increasingly blurred in recent years as larger centers
acquire smaller community-based hospitals which may
then carry the larger academic name, but still operate as a
small, community practice.
The WHO 2016 update now requires pathologists to
perform either IHC or molecular testing in every case of
DLBCL to determine COO2. Given the challenges of
standardizing IHC testing, and lack of access to newer
molecular methods, reporting of COO may be prone to
discordance between practices34. Additionally, with the
inclusion of the entity “high grade B-cell lymphoma, with
MYC and BCL2 or BCL6 rearrangements” in the WHO
2016 lymphoma classiﬁcation, it also becomes critical to
perform FISH to exclude a MYC gene rearrangement in
cases of lymphoma with DLBCL morphology2. In spite of
recommendations by the WHO, this testing is likely to be
variably adopted amongst pathologists, both for reasons of
access to testing and knowledge of the classiﬁcation
changes34. Although E1412 did not require COO deter-
mination or MYC FISH in RT to initiate therapy, having
these data up-front is likely to be critical for future
DLBCL trials, further underscoring the need for rapid,
RT-ECPR and testing in the era of targeted therapy and
precision medicine.
The problem of tissue inadequacy is not unique to
clinical trials, and is an unfortunately frequent occurrence
with the increasing prevalence of core needle biopsy
specimens and the concurrent rise in molecular/genetic
testing in diagnostic pathology. Almost half of all patients
submitted for enrollment on E1412 were diagnosed with
lymphoma on core biopsy. While in most cases adequate
for diagnosis in this study and others35–37, these small
specimens may leave little tissue remaining for necessary
molecular/genetic studies. Accordingly, both the WHO
and NCCN caution strongly against using ﬁne needle
aspirate and core biopsies for the initial diagnosis of
malignant lymphoma2,3. The high ineligibility rate due to
tissue inadequacy in this study emphasizes the continuing
need for larger, preferably excisional, biopsies in the
diagnosis of lymphoma. Not only will this ensure sufﬁ-
cient tissue for possible clinical trial enrollment, but it
ensures adequacy for molecular and genetic tests which
are becoming increasingly required for appropriate diag-
nosis in the routine clinical setting both in academic and
community centers.
King et al. Blood Cancer Journal  (2018) 8:27 Page 6 of 8
Blood Cancer Journal
Within the realm of clinical trials, our process of rapid,
RT-ECPR provides a viable solution for the issues caused
by misdiagnosis and misclassiﬁcation of lymphomas. Prior
to the study modiﬁcation, over 1/3 of study slots were
held by patients who would later become ineligible for the
trial. After institution of RT-ECPR, these study slots were
preserved, along with all of the costs of treating those
patients on study, as patients whose pathology was ineli-
gible were never enrolled on the trial. This results in
savings not only of money and time spent treating these
patients on study, but also may enable those patients to
more efﬁciently receive appropriate therapy at their home
institution.
As obtaining up-front relevant pathology and biomarker
data becomes increasingly important for structuring and
enrolling patients on clinical trials, cooperation between
pathologists and clinicians will be critical. Increasingly,
DLBCL trials are focusing on therapies directed at either
GCB or ABC patients, or those with or without MYC
rearrangements8,7,9,11,14. As this study illustrates, RT-
ECPR is vital for ensuring an appropriate study popula-
tion, and for collection of such data.
While promising, RT-ECPR is not without its limita-
tions. There is no question that time is added prior to
enrollment with ECPR, even when done efﬁciently. To
minimize this, referring centers were encouraged to send
their stained pathology materials, to avoid the additional
time needed to cut and stain slides at the ECPR site.
Additionally, the ECPR pathologists ensured that at least
one pathologist was available every weekday for incoming
cases. Weekends and holidays, however, do result in some
inevitable delays. Bias within clinical trials is already a
concern, as they may select for patients whose disease is
more stable to allow time for enrollment8. To alleviate
these concerns, some recent studies, including E1412,
have allowed for up-front treatment with corticosteroids
as a bridge to beginning therapy on study. E1412 allows
up to 7 days pre-treatment with prednisone, as clinically
indicated, without requiring a washout period8. As our
data clearly illustrates, however, most of the pre-trial time
occurred between the time that the diagnosis was made by
the home institution, and the time the material was sub-
mitted for enrollment to E1412, rather than the time
between submission for enrollment and notiﬁcation of
eligibility.
In summary, the success of this rapid, RT-ECPR for
E1412 exempliﬁes a new era in DLBCL clinical trials and
serves as a model for other lymphoma trials. With
increasing complexity of lymphoma diagnostics, there is a
need for central, uniform pathology review to ensure that
the study cohort accurately represents the population of
interest. Furthermore, RT-ECPR allows for rapid and
organized collection of relevant pathology and biomarker
data essential to trial success.
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